The Supreme Court unanimously ruled that human genes isolated from the body can’t be patented, a victory for doctors and patients who argued that such patents interfere with scientific research and the practice of medicine. The patentability of those isolated genes was challenged by researchers and scientists and other scientists.
Forest Laboratories, Inc. announced today that NAMENDA XR(TM) (memantine hydrochloride) once-daily formulation is now available in pharmacies throughout the United States. NAMENDA XR is approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe dementia of the Alzheimer's type.
On May 30, 2013, Health Canada approved Xtandi for the treatment of patients with metastatic castration-resistant prostate cancer, or mCRPC, who have received prior docetaxel therapy (chemotherapy medication). The announcement was made today by Astellas Pharma Canada, Inc., the Canadian subsidiary of Tokyo-based Astellas Pharma, Inc.
Verastem, Inc. announced that VS-6063 has received orphan medicinal product designation from the European Commission for use in mesothelioma. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.
Doctors should consider giving a daily AIDS drug to another high risk group to help prevent infections — people who shoot heroin, methamphetamines or other injection drugs, U.S. health officials said Wednesday. The latest advice was triggered by the results of a study done in Thailand that showed the AIDS drug tenofovir protected many drug users.
Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the first patient has been enrolled in a Phase 1/2 clinical trial of EPZ-6438 (E7438).
WellDoc®, a healthcare behavioral science and technology company, announced the launch of BlueStar ™, announced a new product in a novel class of diabetes therapy. BlueStar will be reimbursed and adjudicated as a pharmacy benefit similar to other prescription products.
Drug manufacturer GlaxoSmithKline said Thursday it has investigated an accusation that its salespeople in China bribed doctors and found no evidence of wrongdoing. The company said it conducted a four-month investigation after receiving complaints from an anonymous source.
The RTR-505P wireless pulse counting data logger can record pulses from devices such as flow meters, anemometers or the opening and closing of switches from a variety of sensors. The recorded data in the RTR-505P not only can be collected via wireless communication, but can also be used for remote data monitoring and collection, warning monitoring, and data management through networks.
A long-term study from the Mayo Clinic highlights the danger of sleep apnea and its connection to cardiac arrest. Dr. Carol Ash, director of sleep medicine at Meridian Health, talks to the "CBS This Morning" co-hosts about how to recognize the symptoms of this disorder.
The brochure features its Small Flow Element (SFE) line of filters and housings. The SFE filter brochure highlights media options available for filtration, including PVDF, PES, polypropylene, PTFE, borosilicate glass microfiber, polypropylene microfiber, and polypropylene depth.
Amgen and Cytokinetics Incorporated today announced an expansion of their strategic collaboration to include Japan. In 2006, Cytokinetics and Amgen entered into a collaboration to discover, develop and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for potential applications in the treatment of heart failure.
Anacor Pharmaceuticals announced today that it has entered into a loan agreement with Hercules Technology Growth Capital, Inc. for up to $45.0 million in new capital to be distributed in three tranches. Anacor borrowed the first tranche of $30.0 million upon the execution of the loan agreement on June 7, 2013 and used approximately $22.6 million to repay the remaining obligations under its loan agreement.
Pfizer says it has reached a $2.15 billion settlement with a couple of generic drugmakers over sales of their versions of the heartburn drug Protonix. The world's second-largest drugmaker says Teva Pharmaceutical Industries will pay $1.6 billion to Pfizer and Japanese drugmaker Takeda Pharmaceutical.
Teva Pharmaceutical Industries Ltd. announced today that it has entered into a settlement agreement with Wyeth/Pfizer and Altana/Nycomed to resolve all claims relating to Teva’s sales, commencing in December 2007, of its 20 mg and 40 mg generic Protonix ® (pantoprazole sodium) tablets.